Status
Conditions
Treatments
About
In collaboration with approximately 8 centers that specialize in iRBD we will recruit a total of 80 individuals for the study. All subjects will be enrolled into a 2-year longitudinal study where skin biopsies will be performed at 3 sites on each patient at 12-month intervals (baseline, year 1, year 2). Plasma blood collection will be performed at 12-month intervals (baseline, year 1, year 2). Detailed quantified examination, cognitive evaluation, medical history, and questionnaires will be performed at each visit. Additional biomarker, imaging and clinical information (if available) will be obtained for the purpose of determining phenoconversion to clinically apparent synucleinopathy.
Subjects enrolled in the study will have baseline evaluations and follow up visits at 12 and 24 months to define any changes to clinical diagnosis (clinical phenoconversion). Skin biopsies will be repeated at the 12- and 24-month follow up visits to determine the rate of P-SYN accumulation over time and the rates of nerve fiber degeneration within punch skin biopsies.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Subjects with MoCA < 19, Hoehn and Yahr score >/=1, contraindications to skin biopsy
Diagnosis of Parkinson's disease
Diagnosis of dementia of any type
Diagnosis of multiple system atrophy
REM sleep behaviors/disturbances secondary to another cause (e.g., narcolepsy, dementia, and Parkinson's disease)
Contra-indications to skin biopsy:
Loading...
Central trial contact
Aracely Galarza; Jade Stohl
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal